Cargando…

Updates on the Treatment of Erythrodermic Psoriasis

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rari...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Yang, Tsai, Tsen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200157/
https://www.ncbi.nlm.nih.gov/pubmed/34136373
http://dx.doi.org/10.2147/PTT.S288345
_version_ 1783707545655836672
author Lo, Yang
Tsai, Tsen-Fang
author_facet Lo, Yang
Tsai, Tsen-Fang
author_sort Lo, Yang
collection PubMed
description Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.
format Online
Article
Text
id pubmed-8200157
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82001572021-06-15 Updates on the Treatment of Erythrodermic Psoriasis Lo, Yang Tsai, Tsen-Fang Psoriasis (Auckl) Review Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP. Dove 2021-06-09 /pmc/articles/PMC8200157/ /pubmed/34136373 http://dx.doi.org/10.2147/PTT.S288345 Text en © 2021 Lo and Tsai. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Lo, Yang
Tsai, Tsen-Fang
Updates on the Treatment of Erythrodermic Psoriasis
title Updates on the Treatment of Erythrodermic Psoriasis
title_full Updates on the Treatment of Erythrodermic Psoriasis
title_fullStr Updates on the Treatment of Erythrodermic Psoriasis
title_full_unstemmed Updates on the Treatment of Erythrodermic Psoriasis
title_short Updates on the Treatment of Erythrodermic Psoriasis
title_sort updates on the treatment of erythrodermic psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200157/
https://www.ncbi.nlm.nih.gov/pubmed/34136373
http://dx.doi.org/10.2147/PTT.S288345
work_keys_str_mv AT loyang updatesonthetreatmentoferythrodermicpsoriasis
AT tsaitsenfang updatesonthetreatmentoferythrodermicpsoriasis